Share
Pieter Kroese
ScreenPoint Medical has announced a leadership transition, appointing Pieter Kroese as the new Chief Executive Officer, effective immediately. Kroese takes over from Mark Koeniguer, who served as CEO since 2022 and played a key role in the company's commercial success over the past two years. Kroese steps into this role after serving as Chief Operating Officer (COO) for more than five years, overseeing the company's growth from a startup to an established enterprise with hundreds of customers using its flagship Transpara software to assist in millions of breast cancer screenings worldwide.
“I am thrilled to lead ScreenPoint into its next phase of growth and innovation,” said Pieter Kroese. “We are expanding screening capacity through proven reader support, and I look forward to continuing our mission of supporting healthcare providers and women globally.”
Sir Michael Brady, Chairman and co-founder of ScreenPoint, praised Kroese's leadership and his deep understanding of the product and industry. Brady highlighted Kroese’s critical role in the company’s growth and expressed confidence that he will steer ScreenPoint toward continued success.
Dr. Rachel Brem, a board member and Transpara user, echoed these sentiments, noting Kroese’s proven leadership and dedication to early breast cancer detection. She emphasized the positive clinical impact of Transpara worldwide, including in the United States, and expressed confidence in Kroese’s ability to push innovation further.
Related posts
